The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis.
Open accessAbstract
In a randomised, controlled study alternate day prednisolone with an initial high dose phase ("prednisolone only series") has been compared with cyclophosphamide plus alternate day low dose prednisolone ("cyclophosphamide-prednisolone series") in 43 patients with previously untreated fibrosing alveolitis (five patients had received prednisolone in minimal dosage). In the prednisolone only series prednisolone 60 mg daily was given for one month and then reduced by 5 mg a week to 20 mg on alternate days or the minimum dose to maintain early improvement. Patients in the cyclophosphamide-prednisolone series received 100, 110, or 120 mg cyclophosphamide daily (depending on body weight) plus 20 mg prednisolone on alternate days. Treatment was continued indefinitely, or changed to the alternative regimen if the patient deteriorated, failed to improve, or developed drug toxicity. For response to treatment (as judged by change in breathlessness score, radiographic appearance, and lung function) patients were classified as improved, stable, or deteriorating. Deaths from cryptogenic fibrosing alveolitis were also analysed. Improvement had occurred at one or more assessments in seven of the 22 patients in the prednisolone only series and in five of the 21 patients in the cyclophosphamide-prednisolone series. At three years, however, only two of the 22 patients in the prednisolone only series were still improved and three stable, compared with one and seven of the 21 patients in the cyclophosphamide-prednisolone series (three of the seven had stopped treatment because of toxicity). Life table analysis suggested better survival in patients in the cyclophosphamide-prednisolone series but this was not significant. At three years 10 of 22 patients in the prednisolone only series had died compared with three of 21 patients in the cyclophosphamide-prednisolone series. With death or failure of first treatment regimen as outcome there was a significant advantage to the patients having cyclophosphamide-prednisolone. This advantage was explained in part by the better lung volumes in this group on admission. After allowance had been made for total lung capacity (TLC), no other factor was predictive of outcome. Analyses of subgroups according to TLC on admission showed that patients with a TLC below 60% predicted did badly and those with a TLC of 80% or more predicted did well with both regimens. Patients with an initial TLC of 60-79% predicted did better with the cyclophosphamide-prednisolone regimen. Side effects were uncommon in both series and those due to cyclophosphamide resolved when treatment was stopped. The combination of cyclophosphamide with prednisolone may be an alternative to prednisolone alone with an initial high dose phase. Many patients, however, failed to respond to either treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Epidemiology Standardization Project (American Thoracic Society).
Ferris, B. G. (1978) · PubMed · Cited by 1,372
Lung function. Assessment and application in medicine
(1969) · Tubercle · doi:10.1016/0041-3879(69)90013-0 · Cited by 853
Natural History and Treated Course of Usual and Desquamative Interstitial Pneumonia
Carrington, C. B., Gaensler, E. A., Coutu, R. E., FitzGerald, M. X., & Gupta, R. G. (1978) · New England Journal of Medicine · doi:10.1056/nejm197804132981501 · Cited by 791
CRYSTAL, R. G., FULMER, J. D., ROBERTS, W. C., MOSS, M. L., LINE, B. R., & REYNOLDS, H. Y. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-85-6-769 · Cited by 685
Cryptogenic fibrosing alveolitis: clinical features and their influence on survival
Turner-Warwick, M., Burrows, B., & Johnson, A. (1980) · Thorax · doi:10.1136/thx.35.3.171 · Cited by 508
Self-citationMcGavin, C. R., Artvinli, M., Naoe, H., & McHardy, G. J. (1978) · BMJ · doi:10.1136/bmj.2.6132.241 · Cited by 434
Haslam, P. L., Turton, C. W., Lukoszek, A., Salsbury, A. J., Dewar, A., Collins, J. V., & Turner-Warwick, M. (1980) · Thorax · doi:10.1136/thx.35.5.328 · Cited by 249
Self-citationWatters, L. C., Schwarz, M. I., Cherniack, R. M., Waldron, J. A., Dunn, T. L., Stanford, R. E., & King, T. E. (1987) · PubMed · doi:10.1164/arrd.1987.135.3.696 · Cited by 248
The prognosis of cryptogenic fibrosing alveolitis
Stack, B. H. R., Choo-Kang, Y. F. J., & Heard, B. E. (1972) · Thorax · doi:10.1136/thx.27.5.535 · Cited by 240
Diffuse interstitial pneumonitis
Winterbauer, R. H., Hammar, S. P., Hallman, K. O., Hays, J. E., Pardee, N. E., Morgan, E. H., Allen, J. D., Moores, K. D., Bush, W., & Walker, J. H. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90855-0 · Cited by 166
Turner-Warwick, M. E. H., & Haslam, P. L. (1987) · PubMed · doi:10.1164/arrd.1987.135.1.26 · Cited by 165
Self-citationLung Function – Assessment and Application in Medicine
B, J. M. (1980) · Journal of The Royal Naval Medical Service · doi:10.1136/jrnms-66-157a · Cited by 102
Antibodies in some chronic fibrosing lung diseases
Warwick, M. T., & HASLAM, P. L. (1971) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.1971.tb02450.x · Cited by 80
Wright, P. H., Heard, B. E., Steel, S. J., & Turner-Warwick, M. E. H. (1981) · British Journal of Diseases of the Chest · doi:10.1016/s0007-0971(81)80008-3 · Cited by 66
Self-citationTurner-Warwick, M. E. H. (1984) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2007-1011484 · Cited by 18
Self-citation
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964
Metadata
- Authors
- Johnson, M. A., Kwan, S., Snell, N. J., Nunn, A. J., Darbyshire, J. H., & Turner-Warwick, M.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 1989-04-01
- Volume
- 44
- Issue
- 4
- Pages
- 280-288
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2112949206
- Cited by
- 289
- References
- 16
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.